<sub id="d1nvr"><font id="d1nvr"><dfn id="d1nvr"></dfn></font></sub>

    <address id="d1nvr"></address>

    <b id="d1nvr"><cite id="d1nvr"><ruby id="d1nvr"></ruby></cite></b><video id="d1nvr"></video>

    <form id="d1nvr"><var id="d1nvr"><address id="d1nvr"></address></var></form>

    <meter id="d1nvr"></meter>

    <form id="d1nvr"></form>

      INTRODUCTION
      Focus on two main therapeutics, Ophthalmology and Surgical arena of skin surface wounds, while selectively pursue therapeutics in Neurology, Oncology and Orthopaedics
      Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialized biologics marketed in China since 1998.

      The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology & Dermatology, which are marketed and sold through approximately 9000 hospitals and managed directly by its 43 regional sales offices in China.

      Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
      MILESTONES
      1990-2000
      R&D and Manufacturing
      1990
      R&D team established, started the research and development of rb-bFGF
      1996
      Established rb-bFGF API and preparation production plant
      1998
      1st rb-bFGF surgical product Beifuji launched in China
      1999
      1st rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
      2001-2010
      Market Expansion
      2001
      Listed on GEM of HKEx
      2003
      Own sales network in China established
      2005
      2nd generation rb-bFGF products:Beifuxin Gel and Beifushu Eye Gel launched in China
      2006
      Beifushu became a well-known Rx ophthalmic brand in China and entered the forefront of China's ophthalmic prescription drug sales
      2010
      Company’s sales and distribution network enlarged to approximately 1,300 hospitals, managed directly by its 23 regional sales offices in China
      2011-now
      Accelerated Growth
      2011
      Listed on Main Board of HKEx ,stock code: 1061.HK
      2014
      Entered into the Import and Service Agreement with Pfizer
      2014
      New production plant put into operation
      2015
      Initiated Enrichment Programme to leverage external innovation
      2016
      Received a convertible loan of HK$150 million from the International Finance Corporation (IFC) of the World Bank Group
      2018
      Three single-dose eye drops obtained approval from NMPA for comercialisation
      2019
      First global clinical program (VISTA-1) initiated in U.S.
      2019
      3rd generation of rb-bFGF Eye Drops approved for commercialisation in China and entered National Major Scientific and Technological Special Project for“Significant New Drugs Development”
      2020
      The second production plant FUTURE ONE started construction
      2020
      First Overseas Research Centre: U.S Boston Centre opened
      2021
      Positive outcome of VISTA-2
      2021
      Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercilisation in China
      CONTACT US
      Head Office
      in Hong Kong
      Address
      Room 2818, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong SAR, China
      Tel
      (852) 2587 7838
      Fax
      (852) 2587 7363
      Email
      essex@essexbio.com
      Map
      Headquarter
      in Zhuhai
      Address
      No.88, Keji 6th Road, Hi-Tech Zone, Zhuhai, Guangdong, China
      Tel
      (86) 756 3911188
      Fax
      (86) 756 3911185
      Map
      This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
      免费看男生裸体自慰_韩国公和熄2_黑帽门7分40视频_男同志FREEVOIDEOS免费